Premium
Impact of Serum Apolipoprotein A‐IV as a Marker of Cardiovascular Disease in Maintenance Hemodialysis Patients
Author(s) -
Omori Maho,
Watanabe Makoto,
Matsumoto Kei,
Honda Hirokazu,
Hattori Hiroaki,
Akizawa Tadao
Publication year - 2010
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2010.00809.x
Subject(s) - medicine , hemodialysis , creatinine , dialysis , gastroenterology , apolipoprotein b , odds ratio , intima media thickness , endocrinology , cholesterol , carotid arteries
The aim of this study was to investigate the relationship between serum apolipoprotein (apo) A‐IV levels and markers for atherosclerosis, including carotid intima‐media thickness (CIMT) and the ankle–brachial index (ABI), in hemodialysis patients. We performed a cross‐sectional study involving 116 maintenance hemodialysis patients (70 males; median age, 64 years), measuring CIMT, ABI, the usual laboratory examinations, and serum apo A‐IV before the dialysis session. The apo A‐IV concentration was measured by a noncompetitive ELISA. Serum apo A‐IV concentrations were significantly lower in hemodialysis patients with cardiovascular disease and plaque in the carotid artery. The apo A‐IV level was positively associated with urea nitrogen and creatinine, and negatively associated with age, interleukin‐6, the neutrophil/lymphocyte ratio, and maximum CIMT. Moreover, serum apo A‐IV concentrations were significantly lower in the low ABI group. On logistic analysis, patients with high apo A‐IV levels had a lower odds ratio for atherosclerosis (maximum CIMT > 1.0) and cardiovascular disease compared to patients with low apo A‐IV levels. On stepwise multivariate regression analysis, the serum apo A‐IV level was independently associated with creatinine, the neutrophil/lymphocyte ratio, and the maximum CIMT. Serum apo A‐IV is associated with atherosclerotic lesions in hemodialysis patients. Apo A‐IV levels may be useful for estimating the risk of cardiovascular disease in dialysis patients.